These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 10899868)

  • 1. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.
    Wang JY; Noriega FR; Galen JE; Barry E; Levine MM
    Infect Immun; 2000 Aug; 68(8):4647-52. PubMed ID: 10899868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vi Capsular Polysaccharide Produced by Recombinant
    Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
    Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
    J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
    Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
    Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.
    Kantele A; Pakkanen SH; Karttunen R; Kantele JM
    PLoS One; 2013; 8(4):e60583. PubMed ID: 23593253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.
    Wahid R; Pasetti MF; Maciel M; Simon JK; Tacket CO; Levine MM; Sztein MB
    Clin Immunol; 2011 Feb; 138(2):187-200. PubMed ID: 21146460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Killing of Salmonella enterica Serovar Typhi by Antibodies Targeting Vi and Lipopolysaccharide O:9 Antigen.
    Hart PJ; O'Shaughnessy CM; Siggins MK; Bobat S; Kingsley RA; Goulding DA; Crump JA; Reyburn H; Micoli F; Dougan G; Cunningham AF; MacLennan CA
    PLoS One; 2016; 11(1):e0145945. PubMed ID: 26741681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors.
    Pickett TE; Pasetti MF; Galen JE; Sztein MB; Levine MM
    Infect Immun; 2000 Jan; 68(1):205-13. PubMed ID: 10603389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
    Pakkanen SH; Kantele JM; Herzog C; Kantele A
    Vaccine; 2014 Jan; 32(5):544-51. PubMed ID: 24342246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terminal Deoxynucleotidyl Transferase Is Not Required for Antibody Response to Polysaccharide Vaccines against Streptococcus pneumoniae and Salmonella enterica Serovar Typhi.
    Belde V; Cravens MP; Gulandijany D; Walker JA; Palomo-Caturla I; Alugupalli AS; Sandilya VK; Mahmoud T; Bäumler AJ; Kearney JF; Alugupalli KR
    Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29967094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salmonella enterica serovar Typhi live vector vaccines delivered intranasally elicit regional and systemic specific CD8+ major histocompatibility class I-restricted cytotoxic T lymphocytes.
    Pasetti MF; Salerno-Gonçalves R; Sztein MB
    Infect Immun; 2002 Aug; 70(8):4009-18. PubMed ID: 12117906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.
    Wang JY; Pasetti MF; Noriega FR; Anderson RJ; Wasserman SS; Galen JE; Sztein MB; Levine MM
    Infect Immun; 2001 Aug; 69(8):4734-41. PubMed ID: 11447145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B.
    Wahid R; Zafar SJ; McArthur MA; Pasetti MF; Levine MM; Sztein MB
    Clin Vaccine Immunol; 2014 Mar; 21(3):427-34. PubMed ID: 24429069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an attenuated Salmonella enterica serovar Paratyphi A vaccine candidate.
    Xiong K; Chen Z; Zhu C; Li J; Hu X; Rao X; Cong Y
    Int J Med Microbiol; 2015 Sep; 305(6):563-71. PubMed ID: 26239100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression.
    Tacket CO; Levine MM
    Clin Infect Dis; 2007 Jul; 45 Suppl 1():S20-3. PubMed ID: 17582563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant induction of CD4+ and CD8+ T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA.
    Salerno-Gonçalves R; Wyant TL; Pasetti MF; Fernandez-Viña M; Tacket CO; Levine MM; Sztein MB
    J Immunol; 2003 Mar; 170(5):2734-41. PubMed ID: 12594304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential functional patterns of memory CD4
    Salerno-Gonçalves R; Tettelin H; Luo D; Guo Q; Ardito MT; Martin WD; De Groot AS; Sztein MB
    Vaccine; 2020 Jan; 38(2):258-270. PubMed ID: 31629569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.
    Darton TC; Jones C; Blohmke CJ; Waddington CS; Zhou L; Peters A; Haworth K; Sie R; Green CA; Jeppesen CA; Moore M; Thompson BA; John T; Kingsley RA; Yu LM; Voysey M; Hindle Z; Lockhart S; Sztein MB; Dougan G; Angus B; Levine MM; Pollard AJ
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004926. PubMed ID: 27533046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
    Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
    Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.